IPP Bureau
Enhertu to demonstrate a significant survival benefit vs. chemotherapy
By IPP Bureau - December 20, 2022
Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
By IPP Bureau - December 20, 2022
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Guerison to set up footprints in India’s ophthalmology market
By IPP Bureau - December 20, 2022
Global pharmaceutical company having a surgical business concept incepted in Dubai
Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
By IPP Bureau - December 20, 2022
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
By IPP Bureau - December 20, 2022
Positive opinions based on significant survival benefit
4.4 crore health records of citizens digitized and linked with ABHA
By IPP Bureau - December 20, 2022
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
Astellas, Seagen and Merck announce FDA acceptance of sBLA for PADCEV for urothelial cancer
By IPP Bureau - December 20, 2022
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
SRL Diagnostics launches laboratory in Panchkula
By IPP Bureau - December 19, 2022
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet
By IPP Bureau - December 19, 2022
The product is backed by required scientific proof and comparative bioequivalence studies
Aurigene reports results of AUR101 in phase II study in US patients
By IPP Bureau - December 19, 2022
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Stake sale in GMM Pfaudler by Pfaudler
By IPP Bureau - December 19, 2022
Post the sale, Patel family has become the single largest promoter shareholder in the company
Sun Pharmaceutical receives warning letter from USFDA for Halol facility
By IPP Bureau - December 19, 2022
The Halol facility was placed under Import Alert by USFDA.
Mandaviya inaugurates ICMR-NARFBR in Hyderabad
By IPP Bureau - December 19, 2022
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Emmes appoints Ching Tian as Chief Innovation Officer
By IPP Bureau - December 16, 2022
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
